Prosecution Insights
Last updated: July 17, 2026
Application No. 17/771,732

NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES

Non-Final OA §112
Filed
Apr 25, 2022
Priority
Nov 18, 2019 — EU 19209863.0 +3 more
Examiner
RODRIGUEZ-GARCIA, VALERIE
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Bayer Aktiengesellschaft
OA Round
3 (Non-Final)
69%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 69% — above average
69%
Career Allowance Rate
568 granted / 825 resolved
+8.8% vs TC avg
Strong +32% interview lift
Without
With
+31.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
33 currently pending
Career history
859
Total Applications
across all art units

Statute-Specific Performance

§101
2.1%
-37.9% vs TC avg
§103
27.7%
-12.3% vs TC avg
§102
16.5%
-23.5% vs TC avg
§112
32.5%
-7.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 825 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 06/23/2026 has been entered. Receipt of claim amendments filed on 05/22/2026 is acknowledged. Claims 21-28 have been added. Claims 1-14, 19 and 21-28 are pending in this application and are under examination. All rejections and objections have been withdrawn in view of the claim amendments. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 8 and 25-28 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 8 is unclear, it recites PNG media_image1.png 22 118 media_image1.png Greyscale , however, there is no variable or part in the structural formula in claim 8 requiring this definition. Claims 25-28 depend of claim 8 and recite PNG media_image1.png 22 118 media_image1.png Greyscale . However, there is no variable or part in the structural formula in claim 8 or claims 25-28 requiring this definition. Claim 27 is unclear for various reasons: It recites “substituted with two substituents, provided the substituent(s) are not an either carbon adjacent …”. It requires two substituents; thus, it should be substituents and not substituent(s). Regarding “are not an either carbon adjacent…”, maybe applicant means that the substituents are not in either carbon adjacent …”, Claim 27 lacks antecedent basis for PNG media_image2.png 22 156 media_image2.png Greyscale since there is no C=X group in claim 8. Conclusion Claims 8 and 25-28 are rejected. Claims 1-7, 9-14, 19 and 21-24 are in condition for allowance. Any inquiry concerning this communication or earlier communications from the examiner should be directed to VALERIE RODRIGUEZ-GARCIA whose telephone number is (571)270-5865. The examiner can normally be reached Monday-Friday 9:30am-5:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton Brooks can be reached at 571-270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /VALERIE RODRIGUEZ-GARCIA/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Show 1 earlier event
Sep 18, 2025
Response after Non-Final Action
Oct 28, 2025
Non-Final Rejection mailed — §112
Feb 23, 2026
Response Filed
Mar 24, 2026
Final Rejection mailed — §112
May 22, 2026
Response after Non-Final Action
Jun 23, 2026
Request for Continued Examination
Jun 25, 2026
Response after Non-Final Action
Jul 02, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12677832
NOVEL OXADIAZOLE COMPOUNDS FOR CONTROLLING OR PREVENTING PHYTOPATHOGENIC FUNGI
4y 9m to grant Granted Jul 14, 2026
Patent 12673929
PREPARATION METHOD FOR CANNFLAVIN COMPOUNDS
3y 2m to grant Granted Jul 07, 2026
Patent 12662476
HERBICIDAL THIAZOLE COMPOUNDS
4y 1m to grant Granted Jun 23, 2026
Patent 12655119
CRYSTALLIZATION OF CANNABINOIDS
3y 4m to grant Granted Jun 16, 2026
Patent 12643853
CANNABIGEROL PROLINE COCRYSTALS
4y 2m to grant Granted Jun 02, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
69%
Grant Probability
99%
With Interview (+31.6%)
2y 5m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 825 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month